Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Geneva: The World Health Organization (WHO) has issued a global safety alert highlighting the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use ...

A deep learning system achieved an accuracy of more than 90% in distinguishing arteritic from nonarteritic anterior ischemic optic neuropathy using only color fundus images, according to a study ...

As weight loss jabs like Ozempic become ever more popular, doctors are growing increasingly concerned about their gnarly side ...

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, according to a study published online Dec ...

Researchers found that among semaglutide users, the incidence rate of nonarteritic anterior ischemic optic neuropathy was 14.5 per 100,000 person-years. HealthDay News — For individuals with ...

The longer weight loss GLP-1 drugs like Ozempic and Wegovy have been on the market, the more side effects people are ...

June 6 (Reuters) - Novo Nordisk's (NOVOb.CO) popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition that can lead to vision loss, the European ...

WHO is alerting health-care professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicines—Ozempic, ...